This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosman, D. S. Articles by Pasche, B. Search for Related Content PubMed PubMed Citation Articles by Rosman, D. S. Articles by Pasche, B.

TGFBR1*6A Enhances the Migration and Invasion of MCF-7 Breast Cancer Cells through RhoA Activation

¹ Cancer Genetics Program, Division of Hematology/Oncology, Department of Medicine, ² Robert H. Lurie Comprehensive Cancer Center; and ³ Department of Preventive Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Requests for reprints: Boris Pasche, Cancer Genetics Program, Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 North St. Clair Street, Suite 880, Chicago, IL 60611. Phone: 312-695-0320; Fax: 312-695-0318; E-mail: b-pasche{at}northwestern.edu.

Key Words: Breast cancer • TGF-βx • TGFBR1*6A

TGFBR1*6A is a common hypomorphic variant of the type 1 transforming growth factor β receptor (TGFBR1), which has been associated with increased cancer risk in some studies. Although TGFBR1*6A is capable of switching TGF-β growth-inhibitory signals into growth-stimulatory signals when stably transfected into MCF-7 breast cancer cells, the biological effects of TGFBR1*6A are largely unknown. To broadly explore the potential oncogenic properties of TGFBR1*6A, we assessed its effects on NIH-3T3 cells as well as its effect on the migration and invasion of MCF-7 cells. We found that TGFBR1*6A has decreased oncogenic properties compared with TGFBR1. However, TGFBR1*6A significantly enhances MCF-7 cell migration and invasion in a TGF-β signaling–independent manner. Gene expression profiling studies identified two down-regulated genes involved in cell migration and invasion: ARHGAP5, encoding ARHGAP5, and FN1, encoding fibronectin-1 (FN1). ARHGAP5 and FN1 expression was similarly down-regulated in MCF-7 cells stably transfected with a kinase-inactivated TGFBR1*6A construct. Functional assays show that TGFBR1*6A-mediated decreased ARHGAP5 expression is associated with higher RhoA activation, a crucial mediator of cell migration. Extracellular signal-regulated kinase (ERK) activation is also higher in cells that harbor the TGFBR1*6A allele. We conclude that TGFBR1*6A is not an oncogene but enhances MCF-7 cell migration and invasion through RhoA and ERK pathway activation and down-regulates two crucial mediators of this phenotype. These results provide the first evidence that TGFBR1*6A may contribute to cancer progression in a TGF-β signaling–independent manner. [Cancer Res 2008;68(5):1319–28]

This article has been cited by other articles:

				S. M. BOKOBZA, L. YE, H. E. KYNASTON, R. E. MANSEL, and W. G. JIANG Reduced Expression of BMPR-IB Correlates with Poor Prognosis and Increased Proliferation of Breast Cancer Cells Cancer Genomics Proteomics, March 1, 2009; 6(2): 101 - 108. [Abstract] [Full Text] [PDF]

				H. Li, C. Y. Ung, X. H. Ma, B. W. Li, B. C. Low, Z. W. Cao, and Y. Z. Chen Simulation of crosstalk between small GTPase RhoA and EGFR-ERK signaling pathway via MEKK1 Bioinformatics, February 1, 2009; 25(3): 358 - 364. [Abstract] [Full Text] [PDF]

				Q. Zeng, S. Phukan, Y. Xu, M. Sadim, D. S. Rosman, M. Pennison, J. Liao, G.-Y. Yang, C.-C. Huang, L. Valle, et al. Tgfbr1 Haploinsufficiency Is a Potent Modifier of Colorectal Cancer Development Cancer Res., January 15, 2009; 69(2): 678 - 686. [Abstract] [Full Text] [PDF]

				J. Caramel, F. Quignon, and O. Delattre RhoA-Dependent Regulation of Cell Migration by the Tumor Suppressor hSNF5/INI1 Cancer Res., August 1, 2008; 68(15): 6154 - 6161. [Abstract] [Full Text] [PDF]